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Background: The HIV-1 Nef protein is essential for AIDS pathogenesis by its interaction with host cell surface
receptors and signaling factors. Despite its critical role as a virulence factor Nef is not targeted by current antiviral
strategies.
Results: We have determined the crystal structure of the complex formed by a camelid single-domain antibody
fragment, termed sdAb19, bound to HIV-1 Nef together with a stabilizing SH3 domain. sdAb19 forms a stoichiometric
1:1 complex with Nef and binds to a conformationally conserved surface at the C-terminus of Nef that overlaps with
functionally important interaction sites involved in Nef-induced perturbations of signaling and trafficking pathways. The
antibody fragment binds Nef with low nanomolar affinity, which could be attenuated to micromolar affinity range by
site-directed mutagenesis of key interaction residues in sdAb19. Fusion of the SH3 domain to sdAb19, termed Neffin,
leads to a significantly increased affinity for Nef and formation of a stoichiometric 2:2 Nef–Neffin complex. The 19 kDa
Neffin protein inhibits all functions of Nef as CD4 and MHC-I downregulation, association with Pak2, and the increase in
virus infectivity and replication.
Conclusions: Together, sdAb19 and Neffin thus represent efficient tools for the rational development of antiviral
strategies against HIV-1 Nef.
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The human immunodeficiency virus (HIV) is a persistent
pathogen that caused an estimated 1.6 million people
deaths in 2012 [1]. Of the fifteen proteins encoded by the
HIV genome, the three viral enzymes, protease, integrase
and reverse transcriptase are indispensable for the produc-
tion of viral progeny. These enzymes are core targets of
highly active anti-retroviral therapy (HAART) together
with proteins mediating virus entry [2,3]. HAART allowed
considerable success in reducing viral loads beyond detec-
tion levels and elongating patient life expectancy, but the
current therapy is unable to clear the virus due to the per-
sistence of latent reservoirs [4]. Advances for a successful
eradication strategy showed that HAART in combination* Correspondence: matthias.geyer@caesar.de
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unless otherwise stated.with targeted cytotoxic therapy was able to profoundly
deplete productively infected cells of viral RNA [5]. In
addition, many broad and potent donor-derived antibodies
were uncovered in recent years, suggesting they could be
valuable additions to anti-HIV-1 therapies [6]. Yet, the
rapid emergence of drug resistant mutants and the in-
creased worldwide spread of treatment resistant HIV-1
variants pose increasing problems to effective treatment of
HIV-infected patients. One strategy to improve this situ-
ation is the exploitation of additional drug targets that
could be added to the current regiment. Ideally, such tar-
gets comprise viral factors, since interference with host
cell factors may compromise physiological functions or
even viability of host cells.
Besides the structural proteins, HIV-1 encodes four
accessory proteins to facilitate immune evasion and opti-
mize conditions for virus replication [7]. The accessory nef
gene encodes a 24–35 kDa protein that is found in
all primate lentiviruses and is critical for the full patho-
genic potential of these viruses [8]. Nef affects membrane. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sion of surface receptors such as CD4, CD8, CD28, MHC-
I and MHC-II, DC-SIGN and chemokine receptors in
HIV-1 target cells [9]. In addition, Nef also affects signal
transduction through interaction with cellular kinases like
Pak2 and Hck to modulate signaling pathways in infected
cells [9,10]. To achieve this multitude of activities, Nef has
evolved as a versatile adaptor for protein interactions that
lacks intrinsic enzymatic activity. The structure of HIV-1
Nef is characterized by its flexible loop regions that contain
several sequence motifs as an N-terminal myristoylation
site, a central poly-proline PxxP motif for SH3 domain
binding and C-terminal motifs for interaction with clathrin-
associated endosomal adaptor protein complexes [11].
Although compounds interfering with Nef's activity
would be in multiple ways beneficial to the host, Nef is
currently not a target of antiviral measures. The Nef
protein is not essential for replication of HIV in the in-
fected host, yet the protein promotes the progression to
AIDS in humans by the different internalization profiles
found in SIV or HIV infected cells for CD3 and CD4 T
cell receptors [12]. Previously described Nef-interacting
small molecular compounds bind Nef only with relatively
low affinity, and display high cytotoxicity and/or interfere
with only a subset of Nef interactions and functions
[13,14]. The characterization of a camelid single-domain
antibody fragment, termed sdAb19, which binds to HIV-1
Nef with high affinity, has provided an alternative ap-
proach to inhibit the biological activities of Nef [15]. This
12.7 kDa antibody fragment interfered with the CD4
down-regulation activity of Nef, as well as with the as-
sociation of Nef with Pak2 and the accompanying actin
remodeling effects. In addition, sdAb19 was shown to
counteract the Nef-dependent enhancement of virion
infectivity and virus replication, and to be able to rescue
Nef-mediated thymic CD4+ T cell maturation defects in
transgenic mice expressing Nef [15,16]. Here, we de-
scribe the crystal structure of the sdAb19 single domain
antibody in complex with HIV-1 NefSF2 and an engi-
neered SH3 domain of Hck. We provide structural and
functional evidence for the potent inhibition of Nef
caused by occupation of a highly conserved surface epi-
tope at the C-terminus of Nef. These data represent
important findings for the rational development of new
antiviral strategies targeting HIV-1 Nef.
Results
Architecture of the Nef–sdAb19–SH3B6 complex
The Nef–antibody complex was formed by mixing a
purified recombinant form of HIV-1 NefSF2 (45–210) de-
leted of the first 44 N-terminal residues with sdAb19,
and adding the SH3 domain of human Hck, termed
SH3B6 and engineered for high affinity binding to Nef,
to this complex [17,18]. Analytical gel filtration showedthat addition of sdAb19 and SH3B6 to NefSF2 led to for-
mation of a stoichiometric 1:1:1 complex whose elution
volume at an apparent mass of 45 kDa corresponded
well to the calculated mass of 41.6 kDa (Figure 1A). To
characterize the tripartite SH3B6–Nef–sdAb19 complex
formation, we determined the individual binding affin-
ities between Nef and its two complex partners by iso-
thermal titration calorimetry (ITC). The two interacting
domains, SH3B6 and sdAb19, targeted Nef with similar
individual affinities, showing dissociation constants of
19 nM and 39 nM, respectively, for binding to non-
myristoylated NefSF2 (45–210) (Figure 1B,C). To explore
if myristoylation of Nef affects binding to sdAb19, we
used the lipidated protein and performed ITC measure-
ments (Table 1). Myristoylated Nef was prepared by coex-
pression of full length NefSF2 with the N-myristoyl
transferase and addition of myristic acid to the expression
media [17]. The myristoylation reaction was confirmed
by ESI mass spectrometry analysis (Additional file 1:
Figure S1). However, Nef myristoylation showed no ef-
fect on the binding affinity to sdAb19 (Additional file 1:
Figure S2A and Table 1). A similar result was observed pre-
viously for the binding of SH3B6 to myrNef, which was not
affected by the lipid modification of the viral protein [19].
The tripartite protein complex of HIV-1 NefSF2 (45–210,
Δ158-178, deleted of the C-terminal flexible loop encom-
passing residues 158 to 178 of NefSF2), human Hck-SH3B6
(residues 79–138 of human Hck) and sdAb19 (residues
1–118) was purified by gel filtration and crystallized. The
2.1 Å structure was solved by molecular replacement
using the Nef–SH3B6 domain complex as a search model
[19] (Materials and Methods, Additional file 1: Table S1).
sdAb19 folds into a typical immunoglobulin domain closely
resembling known llama single variable (VHH) structures
[20-23]. The SH3B6–Nef–sdAb19 complex adopts an elon-
gated shape and is formed between two subunits (chains
A and B assigned to SH3B6 and Nef, respectively) of one
asymmetric unit cell with the antibody subunit from a
symmetry mate unit cell (chain C' assigned to sdAb19)
(Figure 1D). The Nef–sdAb19 interface covers an aver-
age molecular surface area of 718 Å2, whereas Nef–
SH3B6 covers an interface of 623 Å
2, with no contacts
formed between sdAb19 and SH3B6. This corresponds
in total to 2,683 Å2 buried molecular surface area on
the three proteins upon assembly into the tripartite
complex. The buried interface area of sdAb19 upon
binding to Nef corresponds to 12% of the total solvent
accessible area of the antibody. The two cysteines C24
and C97 of sdAb19, located in close proximity on op-
posing β-strands B and F, were found to be reduced and
did not form an intramolecular disulfide bond in the
crystal (Figure 1D and Additional file 1: Figure S3).
The camelid antibody was raised by immunization of
the llama with recombinant Nef protein from the HIV-1
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Figure 1 Structure of the tripartite SH3B6–Nef–sdAb19 complex. (A) Size exclusion chromatography of Nef supplemented with sdAb19 and
SH3B6 reveals the equimolar hetero-trimeric association of the three subunits. (B) ITC measurement of SH3B6 binding to NefSF2. (C) Binding of the
camelid antibody sdAb19 to HIV-1 Nef showed a dissociation constant of 39 nM. (D) Crystal structure of HIV-1 NefSF2 (beige) in complex with
camelid sdAb19 (green) and the SH3 domain of Hck (light blue). The two Nef interacting proteins bind to opposite surfaces of Nef. The position
of the C-terminal flexible loop in Nef is indicated. Cysteines C24 and C97 in the canonical fold of sdAb19 are reduced in the crystal structure as
shown in the final 2Fo–Fc electron density map displayed at 1 σ (inset). The PDB accession number of the tripartite sdAb19 complex is 4ORZ.
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http://www.retrovirology.com/content/11/1/24Lai allele, residues 57–205 [15]. To further characterize
the sdAb19 binding specificity to different Nef alleles,
we analyzed the commonly used NL4-3 and NA7 Nef
proteins, which share a sequence identity of 85.7% and
89.0% with SF2 Nef, respectively. Whereas binding to
NefNL4–3 was about 2-fold stronger compared to the SF2
allele, the dissociation constant of sdAb19 to NefNA7 was
determined to 118 nM (Additional file 1: Figure S2B,C
and Table 1). The binding affinity to NA7 Nef was thus
3-fold weaker than the affinity determined for sdAb19–
NefSF2 complex formation. Four homologous replace-
ments occur between NL4-3 and SF2 Nef proteins in the
binding interface to sdAb19, including the notable alter-
ation from M198 to valine [24]. Likewise, four changes
are found between NA7 and SF2 Nef, of which the non-
homologous change from proline at position 154 in
NefSF2 to alanine in NefNA7 is the most prominent.
Overall, these changes appear to be moderate as the
affinity varies only six-fold from the tightest binding
allele, NL4-3, compared to the weakest binding allele,
NA7. Off note, all Nef residues in the binding interface
to sdAb19 are completely identical between Bru/Lai Nef
and NL4-3 Nef alleles. As the average sequence identityof Nef proteins from all HIV-1 subgroups is 84% [25],
the diversity of the three analyzed Nef alleles SF2, NL4-
3 and NA7 represents typical variations from the con-
sensus sequence observed in the nature.
The C-terminal flexible loop of Nef is required for cellu-
lar trafficking functions, as e.g. the internalization of CD4
molecules from the cell surface. Truncation of 21 residues
within this C-terminal flexible loop of NefSF2 reduced the
binding affinity to 98 nM suggesting a minor contribution
of the flexible loop to the Nef–sdAb19 binding interaction
(Additional file 1: Figure S2D). The thermodynamic pa-
rameters of the interactions and the binding stoichiome-
tries are listed in Table 1.
Attenuation of sdAb19 binding by mutagenesis
sdAb19 targets Nef mainly by its three complementarity
determining regions (CDRs) (Figure 2A). The buried
surface area of Nef and sdAb19 involves 43 residues ac-
cording to the PDBePISA survey (www.ebi.ac.uk/msd-
srv/prot_int/) (Additional file 1: Figure S3). Of these,
eleven residues in sdAb19 and eleven residues in Nef are
contacting each other within a distance shell of 3.7 Å,
indicating this surface patch as a conformational epitope
Table 1 Thermodynamic parameters of isothermal titration calorimetry measurements
Titration schemea Kd ΔG ΔH ΔS T ΔS n
(nM) (kcal/mol) (kcal/mol) (kcal/mol/deg) (kcal/mol) ([..] / [..])
a.) SH3B6–Nef–sdAb19 complex formation
SH3B6 to NefSF2
b 18.7 −10.55 −22.51 (±0.25) −0.040 −11.96 0.81 (±0.005)
sdAb19 to NefSF2 38.6 −10.11 −11.62 (±0.005) −0.005 −1.51 0.81 (±0.002)
b.) sdAb19 binding to Nef
sdAb19 to myrNefSF2 32.7 −10.20 −14.97 (±0.22) −0.016 −4.77 0.81 (±0.006)
sdAb19 to NefNL4–3 18.5 −10.37 −17.97 (±0.30) −0.025 −7.42 0.88 (±0.007)
sdAb19 to NefNA7 118 −9.45 −12.82 (±0.12) −0.011 −3.34 0.74 (±0.004)
sdAb19 to NefSF2 (Δ flex. loop) 98 −9.55 −10.71 (±0.06) −0.004 −1.16 0.87 (±0.003)
c.) sdAb19 mutant binding
sdAb19 (G102R,S103E) to NefSF2 920 −8.25 −9.93 (±0.56) −0.006 −1.68 0.9 (±0.085)
sdAb19 (D60R) to NefSF2 3700 −7.40 −3.38 (±0.56) 0.014 4.02 0.74 (±0.009)
sdAb19 (triple) to NefSF2 – – – – – –
d.) NefSF2 mutant binding
sdAb19 to NefSF2 (K148E) 1700 −7.86 −8.77 (±0.26) −0.003 −0.89 0.74 (±0.015)
sdAb19 to NefSF2 (M198K) – – – – – –
sdAb19 to NefSF2 (L202K) – – – – – –
e.) Neffin binding to Nef
Neffin to NefSF2 1.6 −12.02 −38.26 (±0.17) −0.088 −26.23 0.66 (±0.001)
Neffin to NefNL4–3 3.9 −11.49 −33.19 (±0.20) −0.073 −21.71 0.65 (±0.002)
Neffin to NefNA7 14.4 −10.72 −34.69 (±0.12) −0.080 −23.97 0.67 (±0.001)
Neffin (triple) to NefSF2 23.3 −10.41 −18.13 (±0.12) −0.026 −7.72 1.08 (±0.004)
aall ITC measurements were performed at 25°C.
bRecombinant Nef proteins refer to: NefSF2 (45–210, C59S, C210A); myrNefSF2 (myr2-210, C59S, C210A); NefNL4–3 (41–206, C206A); NefNA7 (41–206, C206A).
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intermolecular hydrogen bonds and five salt bridges with
only one water molecule buried in the binding interface
(Figure 2B). Eight of the eleven directly interacting resi-
dues in sdAb19 are located in the CDRs (Figure 2C).
Only one residue, N35, of the canonical CDR1 (residues
29–35 according to the definition by Chothia et al. [26])
contributes to the interaction, whereas the majority of
contacts are mediated by residues located in CDR2 (resi-
dues 54–59). The non-canonical, hyper-variable CDR3
region (residues 100–107) instead appears rather short
in sdAb19, and contributes only to a lesser extent to the
interaction (Additional file 1: Figure S3).
To probe the interaction with Nef, we selected three
residues in sdAb19 for site directed mutagenesis. The ra-
tional for choosing these sites was based on their loca-
tion within a complementarity determining region, and
the amino acid changes were designed to maximally
affect the interaction without impairing the solubility of
the antibody. A key residue of sdAb19 in the complex
interface is D60, whose side chain carboxylic group
forms ionic interactions with K148 of Nef and a hydrogen
bond to Y139 (Figure 2B,C). To explore the contributionof D60 in binding to Nef, we mutated this residue to ar-
ginine, introducing thereby a charge reversal at this amino
acid position while retaining the hydrophilic character of
this surface residue. The dissociation constant of the
sdAb19 D60R mutant for binding to NefSF2 was increased
to 3.7 μM as determined by ITC measurements, corre-
sponding to a 100-fold weakening of the binding affinity
(Figure 3A). In addition to this central residue, we chose
two peripheral positions in sdAb19, G102 and S103, which
were mutated to arginine and glutamic acid, respectively.
This double mutation attenuated the binding affinity for
Nef to 920 nM, corresponding to a 23-fold reduction com-
pared to the native sdAb19 (Figure 3B). Only the combin-
ation of all three mutations, D60R/G102R/S103E, in
sdAb19 finally led to a strong reduction in binding affinity,
such that an interaction with Nef could no longer be de-
tected by ITC (Figure 3C). These results showed that the
binding capacity of sdAb19 to Nef can be experimentally
scaled by introducing different substitutions into the key
positions of this antibody fragment.
We tested the sdAb19 mutants in functional experi-
ments for their effect on the Nef-mediated internaliza-
tion of cell surface CD4. Whereas expression of Nef
Figure 2 sdAb19 targets a C-terminal surface epitope on Nef. (A) Binding of sdAb19 to NefSF2. The three complementarity determining
regions are colored yellow (CDR1), red (CDR2), and blue (CDR3), respectively. (B) Residues of CDR2 are significantly involved in the interaction
with Nef. Hydrogen bonds and salt bridges are displayed as dashed lines. (C) Interaction map of Nef and sdAb19 within a distance shell of 3.7 Å.
Hydrophobic and polar interactions between main chain (dots) and side chain (bars) atoms are indicated by dashed lines colored grey and blue,
respectively. For hydrogen bonds and salt bridges the inter-atomic distances are tabulated.
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ternalization of CD4 leading to only a residual 20% CD4
expression remaining at the cell surface (Figure 3D), co-
expression of sdAb19 blocked this effect and restored
surface CD4 expression to levels observed in the control
cells. In contrast, this capacity to counteract the effect
of Nef on CD4 downregulation was lost by the D60R
sdAb19 mutant and the triple-mutant D60R/G102R/
S103E, further establishing the critical role of these resi-
dues for the functionality of sdAb19.
sdAb19 targets a C-terminal surface epitope on HIV-1 Nef
The epitope on Nef that is recognized by sdAb19 en-
compasses a surface patch toward the C-terminus of the
viral protein. A ring of charged residues, E155, R188,
K148, K192, H196, E201 and H203, surrounds hydrophobic
residues I137, V150, M198 and L202 at its center as wellas the polar Y139 and the adjacent G134 (Figure 4A). The
binding interface delineated on the surface representation
of HIV-1 Nef is shown in Figure 4B. This surface patch
is conserved based on the analysis of 1643 alleles of
HIV-1 Nef proteins from subtype B [24]. For ten resi-
dues of the sdAb19 binding interface the degree of se-
quence conservation is between 96% and 99.9%, based
on the analysis of homologous amino acid replacements
(Figure 4B). Only three residues, M198 (89.2%), L202
(77.5%), and I137 (62.2%), share a smaller degree of se-
quence conservation, with the isoleucine being mostly
replaced by threonine. The high degree of sequence
conservation of residues in the binding interface sug-
gests that sdAb19 binds to almost all Nef alleles of the
major HIV-1 subgroups in agreement with previous re-
sults showing that sdAb19 was able to inhibit a broad
panel of Nef proteins from different HIV-1 groups [15].
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Figure 3 Functional analyses of Nef–sdAb19 interactions. (A-C) Mutation of G102R/S103E (B) or D60R (A) or the combined triple mutant
D60R/G102R/S103E (C) in sdAb19 gradually attenuated binding to Nef as determined by ITC measurements. (D) Mutant sdAb19 proteins
abrogate the inhibitory effect of sdAb19 on CD4 internalization. HeLa-CD4 cells were transfected with plasmids for expression of either Nef-GFP or GFP
in combination with the plasmid for expression of wild-type or mutated sdAb19 (1:3 Nef:sdAb19 plasmid ratio). Transfected cells were stained with
phycoerythrin-conjugated anti-CD4 at 4°C, and the surface expression of CD4 in Nef-GFP- or GFP-expressing cells was measured by flow cytometry
(left panel). Results are expressed as the percentage of the mean fluorescence intensity determined in GFP-positive cells relative to that determined
in GFP-negative cells. Values are the means from at least 3 independent experiments. Error bars represent 1 standard deviation from the means.
Transfected cell lysates were analyzed by Western blot (right panel) using anti-c-Myc and anti-β-actin (top), or anti-GFP (bottom) antibodies.
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http://www.retrovirology.com/content/11/1/24Three different residues in Nef, namely K148, M198
and L202, were mutated to probe their contribution to
the recognition by the antibody fragment. As the corre-
sponding residue to D60 in sdAb19, lysine 148 in Nef
was mutated to glutamate in order to break the salt
bridge formation by charge reversal (Figure 4C). Thishighly conserved lysine is in the center of a basic patch
on Nef that forms the binding interface to sdAb19 as
shown in the electrostatic surface display (Figure 4D).
The dissociation constant for K148E increased to 1.7
μM as determined by ITC experiments, corresponding
to a 44-fold weaker binding affinity compared to the
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Figure 4 Delineation of the sdAb19 surface binding epitope on Nef. (A) Display of amino acids on the surface of NefSF2 that interact with
sdAb19. Polar residues E155, R188, K148, K192, H196, E201 and H203 surround hydrophobic residues V150, M198, L202, I137 as well as G134 and
the central Y139 to constitute the binding epitope on Nef. (B) Surface display of the interacting residues in NefSF2. Basic residues are colored blue,
acidic residue are colored red, and hydrophobic residues are colored yellow. The degree of sequence conservation for homologous residues in
HIV-1 Nef alleles, subtype B, is shown in brackets. (C) Hydrophobic interactions are formed between M198 and L202 of Nef with L52 of sdAb19 in
close proximity to the K148Nef–D60sdAb19 salt bridge. (D) Electrostatic surface display of the binding interface for sdAb19 in HIV-1 NefSF2. The elec-
trostatic surface potential is colored from red (−4 kBT) to blue (+4 kBT). (E) Mutation K148E in Nef weakens the interaction by 44-fold compared to
wild type SF2 Nef as determined by ITC.
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fold difference in binding affinity of the sdAb19 mutant
D60R (3.7 μM) and the Nef mutant K148E (1.7 μM)
could result from the different length of the two charged
residues, which leads to either exposure (D60R) or re-
traction (K148E) of the repulsive charge.
Mutation of either residue M198 or L202 in Nef to a
large, basic lysine abrogated binding to sdAb19 in both
cases (Additional file 1: Figure S4), underlining the im-
portance of hydrophobic residues at these positions.
These mutants however did not impair the ability of Nef
to mediate CD4 internalization as shown when expressedin CD4-positive cells (Additional file 1: Figure S5). This
confirms on the one site the structural integrity of Nef
upon these surface mutations. But it also suggests that
residues M198 and L202 as part of the sdAb19 binding
interface in Nef do not overlap with the CD4 binding
surface of Nef. The inhibition of Nef-mediated down-
regulation of CD4 by sdAb19 might instead occur
at different sites of the large interaction surface be-
tween Nef and sdAb19. Together, these results show
that sdAb19 binds to a C-terminal surface epitope of
Nef that overlaps with distinct functions of the viral
protein.
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http://www.retrovirology.com/content/11/1/24Neffin (sdAb19–SH3B6 fusion) forms a 2:2 complex with Nef
We previously showed that fusion of sdAb19 to SH3B6,
termed Neffin, markedly potentiated the binding affinity
to HIV-1 Nef, and increased the efficacy of inhibition
against all Nef functions in infected cells [16,27]. AsA
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http://www.retrovirology.com/content/11/1/24exclusion chromatography revealed a significantly earlier
elution volume for the Nef–Neffin complex compared
to the tripartite SH3B6–Nef–sdAb19 complex generated
from individual protein assembly (Figure 5B). This ob-
servation suggested the formation of a 2:2 Nef–Neffin
complex. Variation of the linker length in Neffin up to
38 residues did not lead to formation of a 1:1 complex
(Additional file 1: Figure S6), which might be explained
by the opposite location of SH3 and sdAb19 binding
surfaces on the structure of Nef. Of note, the very late
retention of Neffin at an elution volume of 17 ml corre-
sponds to the elution profile of the SH3 domain alone,
confirming the building block construction strategy of
this fusion protein. Using ITC experiments, the dissoci-
ation constant between Nef and Neffin was determined
to 1.6 nM (Figure 5C). While the increase in avidity
based on the accumulated strength of both subunits
might not be as high as observed in other cases, e.g.
compared to the 4,000-fold increase seen for the multiva-
lent combination of two VHH fragments [28], it should be
noted that the affinity determined by ITC is at the lower
resolution limit of this technique. Surface plasmon reson-
ance of the NefNL4–3–Neffin interaction showed indeed
binding in the picomolar affinity regime with very low dis-
sociation rates [27].
To analyze the individual contributions of the two
Neffin subunits to the complex formation with Nef, we
introduced the sdAb19 triple mutation D60R/G102R/
S103E to Neffin, named Neffintriple. This mutation re-
duced the binding affinity of Neffintriple to Nef to the
contribution of the SH3B6 domain alone (Figure 5D and
Table 1), in line with the previous observation that the
triple mutation in sdAb19 alone abrogated the interaction
with Nef (Figure 3C). Size exclusion chromatography con-
firmed indeed formation of a 1:1 Nef–Neffintriple complex
taking the expected higher hydrodynamic volume of the
complex by the unbound sdAb19 subunit into account
(Figure 5E).
Neffintriple as well as the Neffin D60R mutant were
tested in functional experiments to study their contribu-
tion to the impairment of the Nef-induced CD4 internal-
ization (Figure 6A). Whereas wild-type Neffin potently
inhibited CD4 down-regulation by Nef, and fully re-
stored CD4 surface expression levels for both NL4-3 and
SF2 Nef alleles, the D60R mutant and the triple mutant
failed to block CD4 down-regulation. This indicates that
SH3 binding alone does not affect Nef's ability to inter-
act with CD4 and connect it to the intracellular traffick-
ing machinery, in line with previous observations [29].
Likewise, mutation of K148E, M198K or L202K in Nef,
which strongly reduced binding to sdAb19, showed
a gradually reduced susceptibility for the inhibition of
CD4 internalization by wild-type Neffin (Figure 6B).
These data indicate a reciprocal correlation betweensdAb19 binding and the ability of Nef to downregulate
CD4. Nef(K148E), which was still able to bind sdAb19 but
with a lower affinity (see Figure 4E), was functionally inhib-
ited by Neffin only when high levels of Neffin were co-
expressed at a 1:8 Nef:Neffin expression plasmid ratio. In
contrast, the M198K and L202K mutants, which failed to
display any affinity for sdAb19 (Additional file 1: Figure S4),
were not or only poorly inhibited by Neffin even at the
highest concentration (Figure 6B). Therefore, the for-
mation of the 2:2 Nef–Neffin complex may lead to an
additional coverage of Nef surfaces that would be other-
wise accessible for interactions with host cell factors
(Figure 6C). This effect might additionally contribute to
the potency of Neffin for the inhibition of all HIV-1 Nef
functions.
Discussion
Here we define the structural basis of HIV-1 Nef inhib-
ition by the camelid-derived sdAb19 antibody fragment.
sdAb19 binds to a C-terminal surface epitope on Nef
that overlaps with multiple interaction sites of the viral
protein. Nef was shown to target the Pak2 serine/threo-
nine kinase by a C-terminal sequence motif that involves
K192 and F195 residues [30]. We find that K192 and
H196 in Nef are directly interacting with sdAb19. These
overlapping surface interaction sites may thus well ex-
plain how the interaction of Nef to Pak2 is impaired by
the tight binding of sdAb19 [16], although other residues
as the N-terminal VGF motif were shown to affect Pak2
binding as well [31].
The interaction with the cytoplasmic internalization
motifs of CD4 and other T cell surface proteins has been
mapped to a hydrophobic sorting motif recognition site
between the two central helices in the core domain of Nef
[32-34]. Although sdAb19 does not directly interact with
residues of Nef that are supposed to mediate the inter-
action with CD4, its close proximity to the C-terminal
flexible loop is likely involved in inhibition of this function.
The C-terminal flexible loop of Nef harbors a di-leucine
based sorting motif as well as flanking acidic motifs whose
presence is required for Nef trafficking functions via con-
tacts with the clathrin-associated adaptor protein machin-
ery [35,11]. Deletion of the central 21 residues in the
flexible loop of Nef reduced the binding affinity to sdAb19
by three-fold. As sdAb19 directly interacts with E155 in
the flexible loop of Nef, this could affect the interaction
of Nef with the endocytic machinery, thus inhibiting
the downstream effects of Nef on cell surface receptor in-
ternalization. In line with this suggestion we previously
showed that sdAb19 disrupted the direct interaction of
Nef with endosomal adaptor protein complexes [16]. The
antibody fragment however had no effect on the subcellu-
lar localization of Nef as previously shown [15]. This ob-
servation is in line with the finding that sdAb19 shows
Nef + sdAb19 SH3B6
Nef sdAb19
SH3B6
Nef
sd
Ab
19
SH3
B6
0
20
40
60
80
100
120
su
rf
ac
e
ex
pr
es
si
on
of
C
D
4
(%
of
G
F
P
ce
lls
)
GFP Nef Nef +
wt
Nef +
D60R
Nef +
triple
Neffin
wt NefNL4-3
wt NefSF2
A
C
anti-β-actin
+ anti-c-Myc
anti-GFP
wt
Neffin
D60R triple
β-actin
Neffin
Nef-GFP
wt NefNL4-3
0
20
40
60
80
100
120
su
rf
ac
e
ex
pr
es
si
on
o f
C
D
4
(%
of
G
F
P
ce
lls
)
GFP wt Nef Nef(K148E) Nef(M198K) Nef(L202K)
wt Neffin
1:0
1:4
1:8
Nef:Neffin
plasmid ratio
B
Figure 6 Binding of sdAb19 in Neffin correlates with the inhibition of CD4 internalization. (A) HeLa-CD4 cells were transfected with
plasmids for expression of either Nef-GFP or GFP in combination with the plasmid for expression of wild-type or mutated sdAb19 (1:3 Nef:sdAb19
plasmid ratio). Transfected cells were analyzed for CD4 cell surface expression and cell lysates were analyzed by Western blotting (inset panels) as
in Figure 3D. (B) HeLa-CD4 cells were transfected with plasmids for expression of either Nef-GFP, mutant Nef-GFP or GFP alone (1:0 plasmid ratio)
or in combination with increasing amounts of the plasmid for the expression of wild-type Neffin (1:4 or 1:8 plasmid ratio) and analyzed for CD4
cell surface expression. (C) Model of the complex formation between Nef and Neffin, consisting of the two individual Nef-binding domains sdAb19
and SH3B6. Formation of a stable 2:2 complex leads to coverage of additional surfaces in Nef that increases the inhibitory potential of Neffin against
Nef functions.
Lülf et al. Retrovirology 2014, 11:24 Page 10 of 13
http://www.retrovirology.com/content/11/1/24similar binding affinities for an N-terminally truncated
Nef 45–210 variant as well as the myristoylated full length
protein. The data confirm that the myristate and the
N-terminal polybasic patch that sustains membrane bind-
ing [36-39] are free to interact with lipid compartments
even in the Nef–sdAb19 complex. These observations
might explain the inhibition of all internalization stimulat-
ing functions of Nef by sdAb19 except for the downregu-
lation of MHC-I, which supposedly does not occur at the
plasma membrane [40]. This additional function is only
abrogated through the coverage of the PxxP motif and
flanking residues on the core domain of Nef by the SH3
domain moiety of Neffin [16].
The distinct 2:2 stoichiometry of the Nef–Neffin com-
plex formation is surprising given that the two constitut-
ing domains, sdAb19 and SH3B6, bind Nef with similar
affinities. While the topology of the interaction as seen
from the structure determination clearly shows howboth molecules bind to opposing sites of Nef separated
by a long distance, it is perhaps unexpected that we did
not observe strings of Nef–Neffin assemblies, where
high aggregates would form through alternating domain
interactions. Such aggregation strings would occur if the
second Neffin molecule binding to a preformed Nef–
(sdAb19-SH3B6)–Nef complex would recruit a third Nef
subunit into this complex. Instead, the sharp elution
profile at a 2:2 molecular mass suggests the specific and
very tight quaternary Nef–Neffin complex formation.
It seems reasonable to propose that such an assembly
could additionally contribute to the inhibitory function
of Neffin, exceeding the combined effects of sdAb19 and
SH3 alone, as additional surfaces of Nef might be cov-
ered through the 2:2 complex formation. A model re-
garding how a 2:2 Nef–Neffin complex assembly could
lead to additional coverage of Nef surfaces is illustrated
in Figure 6C.
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The structural and functional characterization of sdAb19
and Neffin binding to Nef opens a broad avenue for
their rational usage. sdAb19 and Neffin can be used (i)
for basic research as biochemical tools for in vitro analysis
at the molecular and cellular level, where they could impair
intracellular signaling and trafficking pathways mediated
by Nef in infected cells. (ii) They can also be used for
in vivo evaluation of inhibition of the dysregulatory effects
of Nef on the immune system in a relevant animal model
such as HIV-1 infected “humanized” mice. These latter
experiments should also give definitive answer regarding
validation of Nef as a rational target for development of
new antiretroviral strategies. (iii) sdAb19 can be used as a
tool for small chemical compound identification or lead
compound optimization in high throughput assays or drug
design approaches based on the structure of the Nef–
sdAb19 complex. Through binding to the molecular area
recognized by sdAb19, these compounds could mimic the
inhibitory activity of sdAb19 on Nef functions. (iv) sdAb19
or Neffin might ultimately be directly used in HIV treat-
ment through expression in infected cells either by gene
transfer or after development of nano- and micropar-
ticle-based formulation strategies for efficient intracellular
delivery. As both sdAb19 and Neffin proteins can be pro-
duced in high amounts in E. coli, their easy and low cost
production and the possibility to tune their binding affi-
nity to Nef from the sub-nanomolar to the high micro-
molar affinity range might facilitate a broad application in
both academic and pharmaceutical research.
Methods
Plasmid cloning and protein production
Bacterial expression plasmids for HIV-1 NefSF2, the SH3
domain of human Hck, and llama sdAb19 were described
previously [19,27,41]. Expression and purification of full
length myristoylated NefSF2 protein (myr2-210, C59S,
C210A), an N-terminal deletion construct of NefSF2
(45–210, C59S, C210A), and a NefSF2 variant contain-
ing a deletion of the C-terminal flexible loop (45–210,
Δ158-178, C59S, C210A) was performed similarly as
described [17,41]. sdAb19 (1–118) was expressed as
GST-fusion protein in E.coli and purified by affinity
chromatography as described [27].
NefSF2–sdAb19–SH3B6 crystallization
Initial screening for crystallization conditions of the
NefSF2–sdAb19–SH3B6 complex was carried out using a
Mosquito robot (TTP Labtech) with the sitting-drop
method at 293 K and a concentration of 5–15 mg/ml.
About 0.1 μl of protein solution was mixed with 0.1 μl of
reservoir solution from a 70 μl reservoir in 96-well Hamp-
ton 3553 crystallization plates. Initial crystals of NefSF2–
sdAb19–SH3B6 could be obtained in 0.2 M potassiumformate and 20% polyethylene glycol (PEG) 3350. Crys-
tal conditions were optimized to 0.2 M potassium for-
mate, 17.5% polyethylene glycol (PEG) 3350 and 0.35 M
ammonium chloride grown by hanging-drop vapor dif-
fusion in Linbro crystallization plates. Crystals grew
under these conditions within 12 days to a size of 250 ×
40 × 40 μm. For cryo-protection, crystals were trans-
ferred to a solution that contained the reservoir buffer
with additional 25% ethylene glycol. After 5–10 sec-
onds, crystals were flash-cooled in liquid nitrogen.
Structure determination
The native diffraction data were measured from crystals
cooled to cryogenic temperature of 100 K and were re-
corded on beamline X10SA (PXII) of the Swiss Light
Source (SLS) equipped with an MAR 225 CCD detector
(oscillation width per frame, 1°; 400 frames collected) to
2.1 Å resolution. The NefSF2–sdAb19–SH3B6 crystals
were of space group P41 and had unit cell parameters of
a = 73.07, b = 73.07 and c = 71.25 Å. Assuming the pres-
ence of one tripartite complex in the asymmetric unit,
the solvent content of the crystals is 52.02%. The XDS
package [42] was used to process, integrate, and scale
the collected data. The structure was solved with molecu-
lar replacement using the NefSF2–SH3B6 (PDB entry 3RBB
[19]) as a search model in PHASER [43]. The model was
refined by alternating cycles of manual rebuilding in
COOT [44] and minimization in REFMAC5 [45]. Data
collection statistics and refinement parameters are given
in Additional file 1: Table S1. Protein interfaces and ac-
cessible surface areas were calculated with the program
PISA (http://www.ebi.ac.uk/pdbe/). Molecular diagrams
were drawn using PyMOL (http://www.pymol.org/).
Size exclusion chromatography
Analytical gel filtrations of recombinant NefSF2, SH3B6,
sdAb19, Neffin, and all mutants thereof were performed
using a multicomponent Waters 626 LC system (Waters,
MA) equipped with a Superdex S75 (10/300 GL) column
(GE Healthcare). Typically, 100 μl of a 1.5 mg/ml protein
solution was loaded onto the column that was equilibrated
in 10 mM Tris/HCl (pH 9.0), 100 mM NaCl buffer prior
to injection of the protein samples. Gel filtrations were
run at a flow rate of 0.5 ml per minute in 10 mM Tris/
HCl (pH 9.0), 100 mM NaCl onto the S75 column at 4°C
or 20°C. The optical density was monitored at a wave-
length of 280 nm over the time course of the experiment.
Gel filtration experiments were performed repeated times.
Isothermal titration calorimetry
Interaction of HIV-1 NefSF2 with SH3B6, sdAb19 or Neffin
was performed by isothermal titration calorimetry using
a MicroCal iTC200 microcalorimeter (GE Healthcare).
Measurements were carried out in 20 mM Tris/HCl buffer
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at a concentration of 200 μM were stepwise injected from
the syringe to 20 μM NefSF2 placed in the measurement
cell. The change in heating power was observed over the
reaction time until equilibrium was reached. Data were
analyzed using the software provided by the manufacturer.
Cell culture, transfection, flow cytometry, and
immunoblot analysis
Plasmids for expression in mammalian cells of wild-type
Nef fused to the green fluorescent protein (Nef-GFP), as
well as wild-type Myc-tagged forms of sdAb19 and Neffin,
have been described previously [15,16]. Plasmids for ex-
pression of Nef, sdAb19 and Neffin mutants were con-
structed by PCR-mediated site-directed mutagenesis using
specific primers and the wild-type expression vectors as
templates. Cell culture experiments were performed in
HeLa cells stably expressing CD4 similarly as described
[15,16]. CD4 cell surface staining and flow cytometry ana-
lysis were performed as described previously [15]. Protein
expression was analyzed on transfected cell lysates by
Western blot using anti–c-Myc (9E10; Roche) or anti-GFP
(sc-8334; Santa Cruz Biotechnology Inc.) antibodies [16].
Accession numbers
The atomic coordinates and structure factors of the HIV-1
NefSF2–HckSH3-B6–sdAb19 complex have been deposited
in the Protein Data Bank under accession code 4ORZ.
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the SH3B6–Nef–sdAb19 crystal structure. Figure S1. Analytical
characterization of HIV-1 Nef myristoylation. Figure S2. Isothermal titration
calorimetry measurements of sdAb19 titrated to HIV-1 Nef proteins of
different virus strains. Figure S3. Sequence and secondary structure display of
the SH3B6–NefSF2–sdAb19 complex structure. Figure S4. ITC measurements of
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